Heidelberg Pharma has reported further clinical activity from its Phase [...]
Lead multiple myeloma candidate enters Cohort 8; second asset dosed [...]
Heidelberg Pharma has reported further clinical activity from its Phase [...]
Lead multiple myeloma candidate enters Cohort 8; second asset dosed [...]